Clinical trials: Varicella Immunisation
Varicella
Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella Vaccination
Primary objective is to assess the safety of MG1111 until Day 42 using as 2nd vaccination Secondary objective to assess the immunogenicity and safety of MG1111 using as 2nd vaccination
- Trial name
- NCT05422508
- Testing
- MG1111 (BARICELA), VARIVAX, Suduvax
- Where
- South Korea
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
Rubella, Mumps
Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age
The purpose of this study is to compare two measles, mumps and rubella conjugate vaccines (manufactured by GSK and Merck and Company ) in terms of the immune response elicited and safety with a six month follow-up after first…
- Conditions
- Rubella, Mumps, Measles, Measles-Mumps-Rubella Vaccine
- Trial name
- NCT00861744
- Testing
- GSK Biological's investigational vaccine 209762, M-M-R® II (Merck and Co), Varivax®
- Where
- 48 sites in United States, Puerto Rico
- Volunteers
- 1,259 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Zoster
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
The purpose of this study is to evaluate the efficacy of GSK Biologicals' vaccine GSK1437173A in the prevention of Herpes zoster (HZ) in autologous haematopoietic cell transplant recipients 18 years of age and older.
- Trial name
- NCT01610414
- Testing
- Herpes Zoster vaccine GSK1437173A
- Where
- 178 sites in United States, Australia and 26 more
- Volunteers
- 1,877 people
- Sponsor
- GlaxoSmithKline
Varicella (Chickenpox), Varicella Immunisation
Second Dose of Varicella Vaccine in Healthy Children
This study aim to assess the immunogenicity and safety of interchangeable administration of the second dose of varicella vaccine. A total of 300 healthy participants aged 15 months - 12 years will be enrolled.
- Trial name
- NCT07475000
- Testing
- PROVARIX
- Where
- 5 sites in Turkey (Türkiye)
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sinovac (Dalian) Vaccine Technology Co., Ltd.
Measles, Varicella
Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds
This study is undertaken to generate clinical data on GSK Biologicals' combined measles-mumps-rubella-varicella vaccine manufactured with measles and rubella obtained from newly established working seed viruses which are one…
- Conditions
- Measles, Varicella, Mumps, Rubella
- Trial name
- NCT00892775
- Testing
- Priorix-Tetra (combined measles-mumps-rubella-varicella vaccine), GSK Biologicals' 208136, new formulation
- Where
- 6 sites in Singapore, Taiwan
- Volunteers
- 501 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Immunisation, Diphtheria Immunisation
Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants
Primary objectives: To assess the safety profile of each SP0202 formulation and Prevnar 13 in toddlers and infants (after each and any injection).
- Conditions
- Pneumococcal Immunisation, Diphtheria Immunisation, Tetanus Immunisation, Pertussis Immunisation
- Trial name
- NCT04398706
- Testing
- Pneumococcal Conjugate Vaccine formulation 1, Pneumococcal Conjugate Vaccine formulation 2, Pneumococcal Conjugate Vaccine formulation 3
- Where
- 57 sites in United States, Canada and 2 more
- Volunteers
- 852 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Herpes Zoster
Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.
The purpose of this study is to cross-vaccinate and collect safety data in terms of unsolicited Adverse Events (AEs), Serious Adverse Events (SAEs) and potential Immune Mediated Disease (pIMD) from subjects >= 50 Years of age…
- Trial name
- NCT02690207
- Testing
- Herpes Zoster Vaccine GSK1437173A
- Where
- 195 sites in United States, Australia and 16 more
- Volunteers
- 8,687 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Zoster (HZ), Infectious Diseases
A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine
The goal of this clinical trial is to assess the safety and immunogenicity of an srRNA-based vaccine, JCXH-105, in the prevention of Herpes Zoster (Shingles). Subjects will be randomized to receive either JCXH-105 or Shingrix.
- Conditions
- Herpes Zoster (HZ), Infectious Diseases, Shingles
- Trial name
- NCT06581575
- Testing
- JCXH-105, Shingrix
- Where
- 8 sites in United States
- Volunteers
- 467 people, healthy volunteers welcome
- Sponsor
- Immorna Biotherapeutics, Inc.
Herpes Zoster
A Study to Evaluate Immunity to Varicella Zoster Virus After Immunization With V212 Vaccine or Zostavax (V212-003)
A study in two parts (Part A and Part B) to evaluate the responsiveness of various biomarkers of immunity to Varicella-Zoster Virus (VZV) following repeated immunizations with heat treated VZV vaccine V212 or with Zostavax™.
- Trial name
- NCT00886613
- Testing
- V212, Comparator: Zostavax™, VZV Skin Test
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Varicella (Chickenpox), Varicella Immunisation
Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Vietnamese Children
This is a single armed, Phase 3 study to assess the immunogenicity and safety of the varicella vaccine manufactured by Sinovac. A total of 300 healthy participants aged 1-12 years will be enrolled.
- Trial name
- NCT07473427
- Testing
- Varicella Vaccine
- Where
- Vietnam
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sinovac (Dalian) Vaccine Technology Co., Ltd.
Varicella
Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old
This is a randomized, blind, controlled clinical trial of live attenuated varicella vaccines manufactured by Shanghai Institute of Biological Products Co.,Ltd.
- Trial name
- NCT05158777
- Testing
- Live attenuated varicella vaccines manufactured by Shanghai Institute of Biological Products Co.,Ltd., Live attenuated varicella vaccines manufactured by Changchun BCHT Biotechnology Co.,Ltd
- Where
- China
- Volunteers
- 2,480 people, healthy volunteers welcome
- Sponsor
- Shanghai Institute Of Biological Products
Varicella Zoster, Immunization; Infection
Safety Study of NBP608 in Healthy Adult Volunteers
Indication: Protection against varicella and herpes zoster Study Objectives Primary: Safety and tolerability assessment after single dose administration of NBP608 Secondary: immunogenicity assessment after single dose…
- Trial name
- NCT03121638
- Testing
- VARIVAX, ZOSTAVAX, NBP6081
- Where
- South Korea
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- SK Chemicals Co., Ltd.
Varicella, Rubella
Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM
The purpose of this study is to assess non-inferiority of two different vaccination regimens using GSK Biological's MMRV vaccine (two doses at 9 and 15 months) or Priorix™ (9 months) and one dose of MMRV vaccine (15 months) to…
- Conditions
- Varicella, Rubella, Mumps, Measles
- Trial name
- NCT00969436
- Testing
- GSK Biological's investigational MMRV vaccine 208136, Priorix™, Varilrix™
- Where
- 6 sites in India
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
VZV, Varicella Immunisation
Study on Booster Immunization With Varicella Vaccine at Different Intervals
The goal of this clinical trial is to evaluate the immunogenicity and safety of booster immunization of varicella live attenuated vaccine (varicella vaccine hereafter) at different intervals.
- Trial name
- NCT06994052
- Testing
- Varicella vaccine
- Where
- China
- Volunteers
- 412 people, healthy volunteers welcome
- Sponsor
- Sinovac (Dalian) Vaccine Technology Co., Ltd.
Varicella
Immunogenicity and Safety of GSK Biologicals' Live Attenuated Varicella Vaccine (VARILRIXTM).
This study aims to assess the immunogenicity and safety of varicella vaccination in a population of autologous peripheral stem cell/ bone marrow transplantation recipients who have reached at least four months…
- Trial name
- NCT00792623
- Testing
- VarilrixTM
- Where
- 3 sites in Australia
- Volunteers
- 45 people
- Sponsor
- GlaxoSmithKline
Asthma
Varicella Vaccination With Pulmicort
A study to determine whether treatment with Pulmicort in children has any effect on the varicella vaccine
- Trial name
- NCT00641446
- Testing
- budesonide, varicella zoster virus
- Volunteers
- 250 people
- Sponsor
- AstraZeneca
Varicella
Safety,Tolerability and Immunogenicity of Vaccination With VARIVAX in Healthy Indian Children (V210-056)
To observe the safety and tolerability of the administration of VARIVAX in varicella history negative Indian children 12 months to 12 years of age.
- Trial name
- NCT00496327
- Testing
- Varicella Virus Vaccine Live (Oka-Merck)
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Tetanus, Acellular Pertussis
Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With and Without Varicella Vaccine in Healthy Children 4-6 Years
The purpose of the study is to evaluate the immunogenicity and safety of Kinrix when co-administered with varicella (Varivax® [varicella virus vaccine live], Merck and Company) and (measles mumps rubella) MMR vaccines, compared…
- Conditions
- Tetanus, Acellular Pertussis, Diphtheria
- Trial name
- NCT00871117
- Testing
- GSK Biologicals'Kinrix®, Merck and Company's MMRII, Merck and Company's Varivax
- Where
- 11 sites in United States
- Volunteers
- 478 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Varicella
An Open-labelled Clinical Trial of Live Attenuated Varicella Vaccines to Evaluate the Immunity Persistence After Primary Immunization and Safety and Immunogenicity After the Booster Immunization
This is an open-labelled clinical trial of live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd .The purpose of this study is to evaluate the immunity persistence of the single-dose…
- Trial name
- NCT05150392
- Testing
- Investigational live attenuated varicella vaccine
- Where
- China
- Volunteers
- 1,193 people, healthy volunteers welcome
- Sponsor
- Sinovac (Dalian) Vaccine Technology Co., Ltd.
Varicella
An Immunity Persistence Study of Live Attenuated Varicella Vaccine
This an open phase Ⅳ clinical trial of live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd .The purpose of this study is to evaluate the immunity persistence of live attenuated…
- Trial name
- NCT05095701
- Testing
- Investigational Live Attenuated Varicella Vaccine
- Where
- 2 sites in China
- Volunteers
- 703 people, healthy volunteers welcome
- Sponsor
- Sinovac (Dalian) Vaccine Technology Co., Ltd.